Abstract
We present an in-depth analysis of data from drive through testing stations using rapid antigen detection tests (RDT’s), RT-PCR and virus culture, to assess the ability of RDT’s to detect infectious cases. We show that the detection limits of five commercially available RDT’s differ considerably, impacting the translation into the detection of infectious cases. We recommend careful fit-for-purpose testing before implementation of antigen RDT’s in routine testing algorithms as part of the COVID-19 response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded through EU COVID-19 grant RECOVER (grant agreement ID: 101003589).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of leftover diagnostic specimens for assay validation is permitted under Dutch law.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We present an in-depth analysis of data from drive through testing stations using rapid antigen detection tests (RDTs), RT-PCR and virus culture, to assess the ability of RDTs to detect infectious cases. We show that the detection limits of five commercially available RDTs differ considerably, impacting the translation into the detection of infectious cases. We recommend careful fit-for-purpose testing before implementation of antigen RDTs in routine testing algorithms as part of the COVID-19 response.
Data Availability
Data is available upon request
Data Availability
Data is available upon request
Data Availability
Data is available upon request
Data Availability
Data is available upon request
